Vertex Pharmaceuticals earnings were $4.3B for the trailing 12 months ending Mar 31, 2026, with N/A growth year over year. The latest VRTX earnings report on Mar 31, 2026 announced Q1 2026 earnings of $1.0B, down 13.4% from last quarter. For the last reported fiscal year 2025 ending Dec 31, 2025, VRTX reported annual earnings of $4.0B, with -838.1% growth. The next VRTX earnings date is Aug 3, 2026.
VRTX past earnings growth
How has VRTX's earnings growth performed historically?
Vertex Pharmaceuticals Earnings Reports & History FAQ
What were Vertex Pharmaceuticals's earnings last quarter?
Vertex Pharmaceuticals (NASDAQ: VRTX) reported Q1 2026 earnings per share (EPS) of $4.06, up 61.11% year over year. Total VRTX earnings for the quarter were $1.03 billion. In the same quarter last year, Vertex Pharmaceuticals's earnings per share (EPS) was $2.52.
The next VRTX earnings date is Invalid Date. Add VRTX to your watchlist to be reminded of Vertex Pharmaceuticals's next earnings date.
Is Vertex Pharmaceuticals profitable or losing money?
As of the last Vertex Pharmaceuticals earnings report, Vertex Pharmaceuticals is currently profitable. Vertex Pharmaceuticals's net profit (also called net income) for the twelve months ending Mar 31, 2026 was $4.34 billion, a 538.7% decrease year over year.
What was VRTX's earnings growth in the past year?
As of Vertex Pharmaceuticals's earnings date in Q2 2026, Vertex Pharmaceuticals's earnings has grown year over year. VRTX earnings in the past year totalled $4.34 billion.
What are Vertex Pharmaceuticals's earnings expectations?
The current EPS estimate for Vertex Pharmaceuticals's earnings report in Invalid Date is $4.71.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.